Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SPFPL MARION BARDONNET-BANDEL PHARMACIEN : revenue, balance sheet and financial ratios

SPFPL MARION BARDONNET-BANDEL PHARMACIEN is a French company founded 6 years ago, specialized in the sector Gestion de fonds. Based in BELLEVILLE-EN-BEAUJOLAIS (69220), this company of category PME shows in 2024 a net income positive of 147 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Historique financier - SPFPL MARION BARDONNET-BANDEL PHARMACIEN (SIREN 878969393)
Kennzahl 2024 2023 2022 2021 2020
Umsatz N/C N/C N/C N/C N/C
Nettoergebnis 146 554 € -3 785 € 245 709 € 246 245 € 54 342 €
EBITDA -1 747 € -1 874 € -2 165 € -1 841 € -28 418 €
Nettomarge N/C N/C N/C N/C N/C

Umsatz und Gewinn- und Verlustrechnung

In 2024, SPFPL MARION BARDONNET-BANDEL PHARMACIEN generates positive net income of 147 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2020-2024: 54 k€ -> 147 k€.

EBITDA (2024) ?
EBITDA (Betriebsergebnis vor Abschreibungen)
Definition
Ressource générée par l'activité courante, avant amortissements et charges financières.
Formel
Wertschöpfung - Personalkosten - Steuern
Interpretation
Positiv = rentable Tätigkeit

-1 747 €

EBIT (2024) ?
EBIT (Betriebsergebnis)
Definition
Betriebsergebnis, einschließlich Abschreibungen und Rückstellungen.
Formel
EBITDA - Abschreibungen und Rückstellungen + Auflösungen

-1 747 €

Nettoergebnis (2024) ?
Nettoergebnis
Definition
Bénéfice ou perte après toutes les charges, y compris impôts et éléments exceptionnels.
Formel
Ordentliches Ergebnis + Außerordentliches Ergebnis - Ertragsteuern

146 554 €

Chargement du compte de résultat...

Évolution graphique

Anzeigen :

Aktiva

Chargement des données...

Passiva

Chargement des données...

Solvenz- und Verschuldungskennzahlen

The debt ratio (= Financial debt / Equity x 100) stands at 38%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 73%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 5.2 years of cash flow to repay all financial debt. This ratio remains within usual banking standards.

Verschuldungsgrad (2024) ?
Verschuldungsgrad
Definition
Misst das Verhältnis von Schulden zu Eigenkapital.
Formel
(Finanzschulden / Eigenkapital) x 100
Interpretation
< 50% : Faible
50-100% : Moderat
> 100% : Hoch

37.613%

Finanzielle Autonomie (2024) ?
Finanzielle Autonomie
Definition
Anteil des Eigenkapitals an der Gesamtfinanzierung.
Formel
(Eigenkapital / Bilanzsumme) x 100
Interpretation
> 30% : Gute Autonomie
20-30% : Durchschnitt
< 20% : Faible

72.649%

Rückzahlungsfähigkeit (2024) ?
Rückzahlungsfähigkeit
Definition
Anzahl der Jahre zur Schuldenrückzahlung mit dem Cashflow.
Formel
Dettes financières / CAF
Interpretation
< 3 Jahre : Ausgezeichnet
3-5 Jahre : Angemessen
> 5 Jahre : Attention

5.166

Entwicklung der Solvenzkennzahlen
SPFPL MARION BARDONNET-BANDEL PHARMACIEN

Positionnement sectoriel

Debt ratio
37.61 2024
2022
2023
2024
Q1: 0.0
Méd: 8.3
Q3: 92.95
Average

In 2024, the debt ratio of SPFPL MARION BARDONNET-BA... (37.61) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
72.65% 2024
2022
2023
2024
Q1: 4.58%
Méd: 48.37%
Q3: 87.3%
Good

In 2024, the financial autonomy of SPFPL MARION BARDONNET-BA... (72.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
5.17 years 2024
2022
2023
2024
Q1: -0.01 years
Méd: 0.0 years
Q3: 3.02 years
Average

In 2024, the repayment capacity of SPFPL MARION BARDONNET-BA... (5.17) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquiditätskennzahlen

The liquidity ratio (= Current assets / Current liabilities) stands at 54.72. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquiditätsquote (2024) ?
Liquiditätsquote
Definition
Fähigkeit, kurzfristige Schulden mit dem Umlaufvermögen zu decken.
Formel
Umlaufvermögen / Kurzfristige Verbindlichkeiten
Interpretation
> 1.5 : Sehr gut
1-1.5 : Angemessen
< 1 : Risque de liquidité

54.722

Zinsdeckung (2024) ?
Zinsdeckung
Definition
Fähigkeit, Zinsaufwendungen mit dem Betriebsergebnis zu decken.
Formel
EBIT / Zinsaufwendungen
Interpretation
> 3 : Komfortabel
1.5-3 : Acceptable
< 1.5 : Risiko

-93.017

Entwicklung der Liquiditätskennzahlen
SPFPL MARION BARDONNET-BANDEL PHARMACIEN

Positionnement sectoriel

Liquidity ratio
54.72 2024
2022
2023
2024
Q1: 100.7
Méd: 470.56
Q3: 3112.15
Average -50 pts über 3 Jahre

In 2024, the liquidity ratio of SPFPL MARION BARDONNET-BA... (54.72) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
-93.02x 2024
2022
2023
2024
Q1: -71.27x
Méd: 0.0x
Q3: 0.0x
Average

In 2024, the interest coverage of SPFPL MARION BARDONNET-BA... (-93.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Umlaufvermögensbedarf und Zahlungsfristen

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 124 days. Excellent situation: suppliers finance 124 days of the operating cycle (retail model).

Operatives Working Capital (2024) ?
Operatives Working Capital
Definition
Besoin de financement généré par le cycle d'exploitation (stocks + créances - dettes fournisseurs).
Formel
Stocks + Créances clients - Dettes fournisseurs
Interpretation
Negativ = freigesetzte Liquidität
Positiv = Finanzierungsbedarf

0 €

Kundenforderungen (2024) ?
Kundenforderungen (Tage)
Definition
Durchschnittliche Zahlungsfrist für Kunden.
Formel
(Kundenforderungen / Umsatz inkl. MwSt.) x 360
Interpretation
< 45j : Gut
45-60j : Durchschnitt
> 60j : Lang

0 j

Lieferantenverbindlichkeiten (2024) ?
Lieferantenverbindlichkeiten (Tage)
Definition
Durchschnittliche Zahlungsfrist von Lieferanten.
Formel
(Lieferantenverbindlichkeiten / Einkäufe inkl. MwSt.) x 360
Interpretation
Je länger die Frist, desto besser für die Liquidität

124 j

Lagerumschlag (2024) ?
Lagerumschlag (Tage)
Definition
Durchschnittliche Lagerdauer für Waren oder Materialien.
Formel
(Vorräte / Einkaufskosten) x 360
Interpretation
Je niedriger das Verhältnis, desto schneller der Umschlag

0 j

Entwicklung des Working Capital und der Zahlungsfristen
SPFPL MARION BARDONNET-BANDEL PHARMACIEN

Positionnement de SPFPL MARION BARDONNET-BANDEL PHARMACIEN dans son secteur

Vergleich mit der Branche Gestion de fonds

Bewertungsschätzung

Based on 62 transactions of similar company sales in 2024, the value of SPFPL MARION BARDONNET-BANDEL PHARMACIEN is estimated at 1 083 218 € (range 307 553€ - 2 145 970€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2024
62 tx
307k€ 1083k€ 2145k€
1 083 218 € Range: 307 553€ - 2 145 970€
NAF 5 année 2024

Valuation method used

Net Income Multiple
146 554 € × 7.4x = 1 083 218 €
Range: 307 554€ - 2 145 971€

Only this financial indicator is available for this company.

Bewertungsentwicklung

How is this estimate calculated?

This estimate is based on the analysis of 62 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Gestion de fonds)

Compare SPFPL MARION BARDONNET-BANDEL PHARMACIEN with other companies in the same sector:

Voir toutes les statistiques du secteur Gestion de fonds

Frequently asked questions about SPFPL MARION BARDONNET-BANDEL PHARMACIEN

What is the revenue of SPFPL MARION BARDONNET-BANDEL PHARMACIEN ?

The revenue of SPFPL MARION BARDONNET-BANDEL PHARMACIEN is not publicly disclosed (confidential accounts filed with INPI).

Is SPFPL MARION BARDONNET-BANDEL PHARMACIEN profitable?

Yes, SPFPL MARION BARDONNET-BANDEL PHARMACIEN generated a net profit of 147 k€ in 2024.

Where is the headquarters of SPFPL MARION BARDONNET-BANDEL PHARMACIEN ?

The headquarters of SPFPL MARION BARDONNET-BANDEL PHARMACIEN is located in BELLEVILLE-EN-BEAUJOLAIS (69220), in the department Rhone.

Where to find the tax return of SPFPL MARION BARDONNET-BANDEL PHARMACIEN ?

The tax return of SPFPL MARION BARDONNET-BANDEL PHARMACIEN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SPFPL MARION BARDONNET-BANDEL PHARMACIEN operate?

SPFPL MARION BARDONNET-BANDEL PHARMACIEN operates in the sector Gestion de fonds (NAF code 66.30Z). See the 'Sector positioning' section above to compare the company with its competitors.